Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Avanos Medical Inc is a medical devices business based in the US. Avanos Medical shares (AVNS) are listed on the NYSE and all prices are listed in US Dollars. Avanos Medical employs 4,555 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $27.74 |
|---|---|
| 52-week range | $24.54 - $38.92 |
| 50-day moving average | $28.15 |
| 200-day moving average | $31.25 |
| Wall St. target price | $38.50 |
| PE ratio | 68.8601 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $0.39 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $27.74 from 2022-07-01
| 1 week (2022-06-24) | 4.36% |
|---|---|
| 1 month (2022-05-29) | N/A |
| 3 months (2022-03-31) | -17.19% |
| 6 months (2021-12-31) | -19.99% |
| 1 year (2021-07-02) | -22.54% |
|---|---|
| 2 years (2020-07-02) | -8.57% |
| 3 years (2019-07-02) | 42.84 |
| 5 years (2017-06-30) | 39.28 |
Valuing Avanos Medical stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Avanos Medical's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Avanos Medical's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 69x. In other words, Avanos Medical shares trade at around 69x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Avanos Medical's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $66.1 million.
The EBITDA is a measure of a Avanos Medical's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $761.3 million |
|---|---|
| Operating margin TTM | 3.47% |
| Gross profit TTM | $364.3 million |
| Return on assets TTM | 0.97% |
| Return on equity TTM | 1.48% |
| Profit margin | 2.44% |
| Book value | $26.51 |
| Market capitalisation | $1.3 billion |
TTM: trailing 12 months
We're not expecting Avanos Medical to pay a dividend over the next 12 months.
Over the last 12 months, Avanos Medical's shares have ranged in value from as little as $24.54 up to $38.92. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Avanos Medical's is 0.8734. This would suggest that Avanos Medical's shares are less volatile than average (for this exchange).
Avanos Medical, Inc. , a medical technology company, focuses on delivering medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands. The company also provides a portfolio of non-opioid pain solutions, including acute pain products, such as On-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems; and interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.